Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCT641
- Development stage
- Preclinical
- Lead developer
- Sinocelltech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
SCT641 is a recombinant humanized bispecific monoclonal antibody developed by Sinocelltech for the treatment of autoimmune diseases. It is engineered to simultaneously target and neutralize both Interleukin-17A (IL-17A) and Interleukin-17F (IL-17F), two pro-inflammatory cytokines that play a synergistic role in driving chronic inflammation. By dual inhibition of these ligands, SCT641 aims to provide enhanced therapeutic efficacy compared to agents that target IL-17A alone, particularly in conditions such as plaque psoriasis and axial spondyloarthritis. The drug is currently in the preclinical stage of development.
02
Targets
IL17F (Interleukin 17F)IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on SCT641.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCT641.